Preservation of cellular components from cells with a preservative
This invention relates to a preservative solution and a method to preserve whole blood for cellular and molecular analysis.
1. A reagent consisting of: (a) sodium phosphate dibasic heptahydrate; (b) potassium phosphate monobasic; (c) sodium chloride; (d) ethylenediaminetetraacetic acid, disodium salt dihydrate; (e) crosslinked polyethylene glycol (PEG) of 20 k molecular weight; and (f) an effective amount of glyoxal for preserving cells from a biological sample for subsequent isolation of cellular components.
2. The reagent of claim 1 , wherein the effective amount of glyoxal is from about 0.1% to about 0.5%.
3. The reagent of claim 1 , wherein the effective amount of glyoxal is about 0.2%.
4. The reagent of claim 1 , wherein the cells are selected from the group consisting of circulating tumor cells (CTC), circulating melanoma cells (CMC), circulating endothelial cells (CEC), circulating multiple myeloma cells (CMMC), circulating fetal cells, antigen-specific T cells, acute myeloid leukemia stem cells, and dendritic cells.
5. The reagent of claim 1 , wherein the biological sample is whole blood.
6. The reagent of claim 1 , wherein the cellular components are nucleic acids.
7. The reagent of claim 1 , wherein the cellular component is coding RNA.
8. The reagent of claim 1 , wherein the cellular components are selected from the group consisting of mRNA, tRNA, incRNA, rRNA, micro RNA, siRNA, snoRNA, piRNA, tsRNA, and srRNA.
9. A method for preparing a biological sample, comprising (a) contacting a biological sample comprising a plurality of cells with the reagent of claim 1 ; and (b) purifying one or more cells from the biological sample.
10. The method of claim 9 , further comprising (c) extracting cellular components from the one or more cells purified from the biological sample.
11. The method of claim 9 , wherein the effective amount of glyoxal is from about 0.1% to about 0.5%.
12. The method of claim 9 , wherein the effective amount of glyoxal is about 0.2%.
13. The method of claim 9 , wherein the cells are selected from the group consisting of red blood cells, white blood cells, platelets, B-Cells, T-cells, and rare cells.
14. The method of claim 13 , wherein the rare cells are selected from the group consisting of circulating tumor cells (CTC), circulating melanoma cells (CMC), circulating endothelial cells (CEC), circulating multiple myeloma cells (CMMC), circulating fetal cells, antigen-specific T cells, acute myeloid leukemia stem cells, and dendritic cells.
15. The method of claim 9 , wherein the biological sample is whole blood.
16. The method of claim 9 , wherein the cellular components are nucleic acids.
17. The method of claim 9 , wherein the cellular component is coding RNA.
18. The method of claim 9 , wherein the cellular components are selected from the group consisting of mRNA, tRNA, incRNA, rRNA, micro RNA, siRNA, snoRNA, piRNA, tsRNA, and srRNA.
19. The method of claim 9 , wherein (a) contacting the biological sample with the reagent comprises preserving cellular components in the one or more cells.
20. The method of claim 9 , wherein the biological sample is selected from the group consisting of bone marrow, urine, pleural effusions, saliva, lymph node fluid, and plasma.